Epilepsy Pipeline Tracker

 
The mission of the Epilepsy Foundation includes accelerating new therapies for people living with epilepsy and seizures. As a reflection of our commitment and as a service to the community we are pleased to provide here the pipeline of epilepsy therapies in various stages of development. We thank all of the individuals and organizations whose efforts are reflected in these seeds of hope. The Epilepsy Foundation makes no claims of accuracy of the following data. Although every effort is made to continuously update this list, some errors are inevitable. Companies or academicians or others who are directly involved with any of the therapies listed here are strongly encouraged to keep us updated by contacting contactus@efa.org of any needed changes.
NEW DRUGS IN DEVELOPMENT edit

ACT-709478

  • PRE
  • P1
  • P2
  • P3
Sponsors / Collaborators Actelion (J&J company) / Idorsia Pharmaceuticals Ltd.
Mechanism of Action |Ion Channel : Selective T-type Calcium Channel Blocker
View Details
NEW FORMULATIONS AND INDICATIONS edit

ADS-4101

  • PRE
  • P1
  • P2
  • P3
Sponsors / Collaborators Adamas Pharmaceuticals, Epilepsy Foundation (EF)
Mechanism of Action |New Formulation : Voltage Gated Sodium Channels (modified release of lacosamide)
View Details
NEWLY MARKETED edit

Afinitor / Votubia (Everolimus)

Mechanism of Action |mTOr : mTOR Inhibitor
Type of Drug / Device New Molecular Entity
Company / Institution Novartis
View Details
NEW DIAGNOSTIC TOOLS edit

Airbag Head Protection for People with Epilepsy

Phase of Development Pivotal Phase
Sponsors / Collaborators Hovding Sverige AB, Epilepsy Foundation (EF)
Mechanism of Action |Head Protection : N/A
Software/Hardware/Both Hardware
View Details
XLSX

Our Mission

The mission of the Epilepsy Foundation is to lead the fight to overcome the challenges of living with epilepsy and to accelerate therapies to stop seizures, find cures, and save lives.

 
24/7 helpline
P